LTS Breaks Ground on Major Expansion to Advance Drug Delivery Innovation and North American Growth
LTS today celebrated the groundbreaking of a major expansion project at its West St. Paul, Minnesota campus.
Repurposing approved therapies as nasal sprays
Nasal spray repurposing through the 505(b)(2) regulatory pathway has emerged [...]
The potential of foam-based oral thin films for faster, more flexible drug delivery
OTFs are well established as an important non-invasive route for drug administration. Placed on or under the tongue or buccally, they are absorbed by the oral mucosa with the active substance directly transported into the bloodstream.
Securing high level partner and patient engagement through non-invasive drug delivery innovation
It is only in true market leader organisations that pure innovation is encouraged, with experts devoting time to genuine research alongside their operational responsibilities.
LTS recognized again as a Best Managed Company – third consecutive award
LTS Lohmann Therapie-Systeme AG has once again been named a Best Managed Company, marking the third consecutive year the company has received this prestigious recognition.
Nasal spray development: Key formulation and device considerations for combination nasal drug products
Because nasal sprays are defined as combination products, it can [...]
Responsible Care® at LTS
LTS has joined the Responsible Care® Initiative of the International Council of Chemical Associations (ICCA).
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
LTS announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions.
LTS joins UN Global Compact network
LTS is a member of the UN Global Compact Network, the world’s largest initiative for sustainable and responsible corporate leadership.
Advancing biologics and vaccine delivery with Microneedle Array Patch (MAP) Technology
In our webcast Dr. May Pidding explains how clinically needs-driven [...]